Paper39701340
Impact of nanoparticle properties on immune cell interactions in the lymph node.
Farooq MA and 2 others. Acta Biomater, 2025. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Impact of nanoparticle properties on immune cell interactions in the lymph node. Papers, record 39701340. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39701340
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lymph Nodes | Major topic |
| Nanoparticles | Major topic |
| Cell Communication | Major topic |
| Humans | |
| Animals |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42922362 | Physicochemical design principles for B cell targeted acetalated dextran microparticles in antigen-specific tolerance for multiple sclerosis. | Biomater Sci | 2026 | https://conductscience.org/library/papers/42922362 | PubMed |
| 42826091 | Engineered nanovaccines for prophylactic and therapeutic immunotherapy against cancer and infectious disease. | Hum Vaccin Immunother | 2026 | https://conductscience.org/library/papers/42826091 | PubMed |
| 42662463 | Increasing hydrophobicity in poly(amino acid) adjuvants elicits potent and durable anti-tumor immunity via coordinated cellular and humoral responses. | Bioact Mater | 2027 | https://conductscience.org/library/papers/42662463 | PubMed |
| 42540442 | Augmented therapeutic efficacy of Erianin through pH-responsive charge-reversal liposome integrated synergistic PTT and PDT in breast cancer. | J Pharm Anal | 2026 | https://conductscience.org/library/papers/42540442 | PubMed |
| 42513179 | Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures. | Molecules | 2026 | https://conductscience.org/library/papers/42513179 | PubMed |
| 42434845 | Nanoplatforms for Sentinel and Tumor-Draining Lymph Node Mapping: From Visualization to Pathway-Informed Staging. | Adv Healthc Mater | 2026 | https://conductscience.org/library/papers/42434845 | PubMed |
| 42272984 | Tissue-specific gene delivery approaches. | Bioeng Transl Med | 2026 | https://conductscience.org/library/papers/42272984 | PubMed |
| 42218454 | Rewiring the immune circuit: programming tumor-draining lymph node immunity with nanotechnology. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42218454 | PubMed |
| 42159453 | Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42159453 | PubMed |
| 42120401 | Interventions and platforms that direct lymphangiogenesis to restore physiological homeostasis and enhance immunoregulation. | NPJ Regen Med | 2026 | https://conductscience.org/library/papers/42120401 | PubMed |
| 42005704 | Exosomes as Emerging Nanocarriers for Targeted Cancer Therapy. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/42005704 | PubMed |
| 41847953 | Innovative γ-Oryzanol and KC2 Based Lipid Nanoparticles: OryKL Platform Provides Safe and Efficient In Vivo mRNA Delivery. | Small | 2026 | https://conductscience.org/library/papers/41847953 | PubMed |
| 41822464 | Microneedle-based transdermal delivery systems for metabolic bone diseases: advances, challenges, and future perspectives. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/41822464 | PubMed |
| 41648598 | Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunity. | bioRxiv | 2026 | https://conductscience.org/library/papers/41648598 | PubMed |
| 41537174 | Regulatory T Cells and Nanomaterials: Dual Perspectives in Therapeutics and Immunomodulation. | Small Sci | 2026 | https://conductscience.org/library/papers/41537174 | PubMed |
| 41471111 | Oral Treatment of Obesity by GLP-1 and Its Analogs. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41471111 | PubMed |
| 41376820 | Engineering Nanoparticles to Modulate Extracellular Matrix and Immune Components of the Tumor Microenvironment in Cancer Immunotherapy. | Biomater Res | 2025 | https://conductscience.org/library/papers/41376820 | PubMed |
| 41357193 | Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/41357193 | PubMed |
| 41235367 | Polyethyleneimine-modified Laminarin nanoparticles enhance antigen delivery to lymph nodes by inducing transient inflammatory responses at the injection site. | Mater Today Bio | 2025 | https://conductscience.org/library/papers/41235367 | PubMed |
| 40741064 | Evaluation of oral and injectable liposome-based vaccines with synthesized lipid for Japanese encephalitis virus in Sprague-Dawley rats. | Clin Exp Vaccine Res | 2025 | https://conductscience.org/library/papers/40741064 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39701340
GET https://conductscience.org/api/papers/v1/39701340/cited_by?page=2